Search clinical trials for: Docetaxel (XRP6976)

Total 2207 results

Sanofi

Completed

Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer

Cancer

United States, France, Canada, Russian Federation, Portugal, Argentina
Sanofi

Completed

NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)

Head and Neck Neoplasms

Tunisia, Morocco, Algeria
Sanofi

Completed

Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer (SWITCH)

Prostatic Neoplasms

Brazil
Sanofi

Completed

Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer

Therapy, Prostatic Neoplasms

Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

Advanced Neoplastic Disease
Sanofi

Completed

Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

Carcinoma | Nasopharyngeal Neoplasms

France, Korea, Republic of, Turkey, Algeria, Brazil, China, India, Indonesia, Italy, Mexico, Morocco, Philippines, Thailand, Tunisia
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Neoplasm Malignant

China
Sanofi

Completed

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)

Prostate Cancer

Australia, Portugal, Spain, Peru, Sweden, Romania, Russian Federation, Belarus, Israel, France, Italy, Denmark, Turkey, Germany, United States, Brazil, Canada, China, Czechia, Finland, Japan, Mexico, Poland, Taiwan, Ukraine
Sanofi

Completed

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Neoplasms | Neoplasm Metastasis | Neoplasm Recurrence, Local

Russian Federation, United States, Canada, Germany, Hungary, Italy, South Africa, Argentina, Uruguay, Austria, Switzerland, Israel, Belgium, France, Australia, Brazil, Greece, Guadeloupe, Réunion, Spain
Sanofi

Completed

Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer

Stomach Neoplasm
Sanofi

Completed

Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)

Breast Cancer | Prostatic Neoplasms

Australia
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
Azaya Therapeutics, Inc.

Completed

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non-Small Cell Lung

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma

United States
Sanofi

Completed

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (TAXYNERGY)

Prostate Cancer Metastatic

United States, Canada
Korean Breast Cancer Study Group

Unknown

A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer (STORM)

Metastatic Breast Cancer | Recurrent Breast Cancer

Korea, Republic of
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Sanofi

Completed

Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck (DECIDE)

Squamous Cell Carcinoma of Head and Neck

Pakistan
Sanofi

Completed

Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer (PRODIGY)

Gastric Cancer

Korea, Republic of
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Nereus Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Cancer

United States, Australia, India, Chile, Brazil, Argentina
Fudan University

Unknown

A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC

Gastric Cancer

China
Academy Military Medical Science, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Advanced Breast Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Zhuhai Beihai Biotech Co., Ltd

Completed

A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours

Solid Tumours | Bioequivalence | Docetaxel

India
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Completed

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
National Cancer Center, Korea
Seoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaborators

Unknown

Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer

Gastric Cancer

Korea, Republic of
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

China
Optimal Health Research

Completed

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Breast Cancer | Lung Cancer | Prostate Cancer

United States
Sanofi

Terminated

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA) (Rising PSA)

Prostatic Neoplasms

United States, Canada, Spain, Slovakia, Belgium, Czech Republic, Lithuania, Germany, Poland
Arog Pharmaceuticals, Inc.

Withdrawn

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim

Completed

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Carcinoma, Non-Small-Cell Lung

Japan
First People's Hospital of Foshan

Unknown

The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Sanofi

Completed

Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer (TAX200006)

Head and Neck Neoplasms

France
Sanofi

Completed

Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

France, Netherlands, Spain, Turkey, Belgium, Finland, Italy, United Kingdom
Fudan University

Not yet recruiting

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

Advanced Non-Small Cell Lung Cancer
Hunan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People's...

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Australian and New Zealand Urogenital and Prostate...
Peter MacCallum Cancer Centre, Australia

Recruiting

Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (GUIDE)

Castration Resistant Prostatic Cancer

Australia
Sanofi

Completed

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Squamous Cell

Austria
Seoul National University Hospital
Clinical Research Center for Solid Tumor, Korea

Terminated

Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
University of Oxford

Unknown

Docetaxel With or Without AZD6244 in Melanoma (DOC-MEK)

Melanoma

United Kingdom
Shenyang Pharmaceutical University

Unknown

Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients

Advanced Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Terminated

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Non Squamous Non Small Cell Lung

China
Peng Wang, MD PhD

Withdrawn

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer

United States
Cristal Therapeutics

Completed

A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NAPOLY)

Cancer | Metastatic Cancer | Solid Tumors

Netherlands, Belgium
European Organisation for Research and Treatment...
GlaxoSmithKline

Completed

Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

Breast Cancer

France, United Kingdom, Belgium, Switzerland, Slovenia
Sanofi

Completed

Docetaxel and Oxaliplatin in Gastric Cancer

Stomach Neoplasms

France, Russian Federation, Portugal, Spain, United States, Turkey, Belgium, Hungary, Italy, United Kingdom, Germany, Switzerland
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CCND1 Gene Amplification | CCND2 Gene Amplification | CCND3 Gene Amplification | CDK4 Gene Amplification | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States

Search clinical trials for: Docetaxel (XRP6976)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations